Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Boehringer Ingelheim Seeks Japan Approval for Nintedanib
October 21, 2014
- Alexion Submits NDA for Hypophosphatasia Treatment Asfotase Alfa
October 20, 2014
- Seikagaku Establishes Representative Office in US
October 20, 2014
- Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
- AMO Japan Appoints Shoko Suzuki of Coca-Cola Japan as New President
October 20, 2014
- Takeda, euglena Strike Comprehensive Collaboration Deal for Euglena-Containing Product Development
October 20, 2014
- Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
- Bayer HealthCare Signs Two-Year Collaborative Search Activity Agreement with Kyoto Univ.
October 17, 2014
- FDA Gives Priority Review Status to Lenvatinib, Rufinamide: Eisai
October 17, 2014
- Pfizer Japan Voluntarily Recalls Torisel Due to Microparticles in Diluent
October 17, 2014
- EPS to Take Full Control of EP-Mint in January
October 16, 2014
- Mochida Hooks Up with LG Life Sciences on Adalimumab Biosimilar
October 16, 2014
- Daiichi Sankyo Launches Tender Offer for US Biotech Ambit
October 16, 2014
- FDA OKs World’s 1st Oral Combination Drug for CINV: Helsinn, Eisai
October 16, 2014
- Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
October 16, 2014
- Kyorin Licenses Uritos to R-Pharm of Russia
October 15, 2014
- Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
- Fujifilm’s Overseas Subsidiaries Develop High-Performance Mammalian Expression Platform
October 14, 2014
- Velcade Approved in US for Treatment-Naïve Mantle Cell Lymphoma: Takeda
October 14, 2014
- GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…